Publications by authors named "D Ettinger"
Article Synopsis
- The NCCN Guidelines for Non-Small Cell Lung Cancer offer comprehensive recommendations for diagnosing and managing NSCLC, including ongoing monitoring and treatment options.
- Recent updates include new targeted therapies approved by the FDA, reflecting the latest clinical data.
- The guidelines specifically highlight treatment strategies for advanced or metastatic NSCLC that have actionable molecular biomarkers.
Article Synopsis
- * Pleural mesothelioma is the most common type, accounting for about 85% of all cases.
- * The NCCN Guidelines for Mesothelioma: Pleural provide updated recommendations on diagnosis, treatment, and follow-up, with recent revisions focusing on disease classification and systemic therapy options.
Unlabelled: While tyrosine kinase inhibitors (TKI) have shown remarkable efficacy in anaplastic lymphoma kinase (ALK) fusion-positive advanced non-small cell lung cancer (NSCLC), clinical outcomes vary and acquired resistance remains a significant challenge. We conducted a retrospective study of patients with ALK-positive NSCLC who had clinico-genomic data independently collected from two academic institutions (n = 309). This was paired with a large-scale genomic cohort of patients with ALK-positive NSCLC who underwent liquid biopsies (n = 1,118).
View Article and Find Full Text PDFObjectives: Understand from a real-world cohort the unique clinical and genomic determinants of a durable response to immune checkpoint inhibitors (ICIs).
Materials And Methods: This is a retrospective study of patients with NSCLC who received any ICI-based regimen as first or second line therapy. Long-term responders (LTR) achieved an overall survival (OS) ≥ 3 years from time of treatment start, while nonresponders (NR) were patients who had an OS of 6 to 12 months from time of treatment start.
Purpose: Although immunotherapy is the mainstay of therapy for advanced non-small cell lung cancer (NSCLC), robust biomarkers of clinical response are lacking. The heterogeneity of clinical responses together with the limited value of radiographic response assessments to timely and accurately predict therapeutic effect-especially in the setting of stable disease-calls for the development of molecularly informed real-time minimally invasive approaches. In addition to capturing tumor regression, liquid biopsies may be informative in capturing immune-related adverse events (irAE).
View Article and Find Full Text PDF